Immunovia AB (publ)

OM:IMMNOV Stock Report

Market Cap: SEK 92.7m

Immunovia Management

Management criteria checks 0/4

Immunovia's CEO is Jeff Borcherding, appointed in Apr 2023, has a tenure of 1.67 years. directly owns 0.21% of the company’s shares, worth SEK191.10K. The average tenure of the management team and the board of directors is 1.8 years and 2.6 years respectively.

Key information

Jeff Borcherding

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.7yrs
CEO ownership0.2%
Management average tenure1.8yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Apr 20
Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Dec 09
We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

May 13
Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18
Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28
We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Mar 09
What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03
Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

CEO

Jeff Borcherding (51 yo)

1.7yrs

Tenure

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

Leadership Team

NamePositionTenureCompensationOwnership
Jeff Borcherding
Global Chief Executive Officer & President1.7yrsno data0.21%
SEK 191.1k
Karin Liwendahl
Chief Financial Officer2.7yrsno datano data
Lara Sucheston-Campbell
Head of Clinical & Medical Affairs1.8yrsno datano data

1.8yrs

Average Tenure

Experienced Management: IMMNOV's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Peter Hongaard Andersen
Independent Chairman4.6yrsSEK 475.00kno data
Hans Johansson
Independent Director8.9yrsSEK 280.00k0.027%
SEK 25.2k
Michael Lofman
Independent Director1.6yrsSEK 175.00kno data
Valerie Bogdan-Powers
Independent Director1.1yrsSEK 16.00kno data
Melissa Farina
Independent Director1.1yrsSEK 16.00kno data
Martin Moller
Independent Director3.6yrsSEK 302.00kno data

2.6yrs

Average Tenure

57yo

Average Age

Experienced Board: IMMNOV's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 17:35
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovia AB (publ) is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lars HevrengDanske Bank
Juan Pedro Rodríguez SerrateEdison Investment Research
Alexandru CogutKempen & Co. NV